Dr. Reddy's launches gSuboxone
Dr Reddy Lab Dr. Reddy's Laboratories has
announced that it is launching generic of Buprenorphine and Naloxone Sublingual
Film (Suboxone) following a final USFDA approval in the US market.
The product is being launched with USFDA’s
approved Risk Evaluation and Mitigation Strategy (REMS) Program. US Company,
Mylan has also launched this drug in the US market. Considering that the patent
on this drug is still valid, this is at risk launch.
Buprenorphine and naloxone are used to
treat adults with opioid dependence/addiction. The combination of these
medications is used as part of a complete treatment program including
prescription monitoring, counselling, and psychosocial support. The launch has
been very important as per the USFDA’s recent statements indicating increasing
opioid addiction in America.
Maruti Suzuki likely to bid adieu to
Ignis Diesel variant
India’s largest passenger vehicle (PV)
manufacturer Maruti Suzuki India Limited (MSIL) is likely to stop production of
diesel variant of its hatchback Ignis, as per media reports. The Ignis was
launched in January 2017 with both variants – petrol and diesel. While the
petrol variant will be retained, diesel version will be likely discontinued.
Several reasons could be responsible for the decision.
Firstly, the steep pricing proved to be a
deterrent. While the petrol Ignis is priced between Rs4.66Lakh and Rs6.51Lakh,
the diesel variant ranges between Rs6.32Lakh and Rs8.12Lakh (ex-showroom price
in New Delhi as per website www.cardekho.com).
Secondly, consumers are increasingly sceptical of owning diesel cars given that
price difference between diesel and petrol in the retail market (fuel pumps) is
narrowing. As per media reports, about 90% of Ignis models sold so far have
been petrol variants and only 10% have been diesel variants. Lastly, it makes
more sense for MSIL to free up capacity for its best-selling models rather than
continuing with laggards.
Avanti Feeds surges after shareholders
approve stock split
Avanti Feeds registered gains at the
equity market after it announced its decision to sub-divide equity shares from
face value of Rs2 each to Rs1 each. Further, it decided to issue bonus equity
shares of Rs1 each in the ratio of 1:2, that is, one equity share of Rs1 each
for every two and equity shares of Rs1 each (after sub-division of shares).
Shareholders approved this recommendation with the requisite majority.This
could be good news for the company.
The company is a leading manufacturer and
exporter of shrimp feeds and shrimp processor. It also operates wind mill with
an installed capacity of ~3.2 megawatt in Karnataka. It derived ~83% revenue
from shrimp feeds and ~17% revenue from processed shrimp during FY18. The total
feed capacity stands at six lakh tonnes per annum as on March 31, 2018.
Alembic Pharma rises on getting EIR from
USFDA for Panelav unit
Alembic Pharmaceuticals Alembic
Pharmaceuticals is currently trading at Rs520.35 up by Rs13.8 or 2.72% from its
previous closing of Rs506.55 on the BSE. The pharma company said it received
establishment inspection report (EIR) from USFDA for the inspection carried out
by them at the company’s formulation facility at Panelav during the period from
March 1, 2018 to March 20, 2018.
On Thursday, the firm announced during
trading hours that day that it has received approval from USFDA for its ANDA
for Doxycycline Hyclate capsules USP, 50mg and 100mg. The approved ANDA is
therapeutically equivalent to the reference listed drug product (RLD),
Vibramycin capsules, 50mg and 100mg, of Pfizer Inc.
NBCC bags contracts worth Rs480.6cr in
May
NBCC NBCC (India) is currently trading at
Rs85.50 up by Rs0.2 or 0.23% from its previous closing of Rs85.30 on the BSE.
The company has secured the total business
of Rs480.65cr (approx) in the month of May, 2018.
NBCC is a Navratna PSU engaged in the
business of project management consultancy (PMC), real estate and EPC. PMC and
redevelopment comprises 87%, real estate and EPC forms 13% of the company’s
order book. Through PMC, the company has been executing many landmark projects.
visit us: www.capitalstars.com/
call on:9977499927
O731-6690000
Get more details here:-
* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
No comments:
Post a Comment